Janssen Biotech Inc.

04/14/2019 | Press release | Distributed by Public on 04/14/2019 22:29

INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study